What is the level of liabilities of Biotest this year?
Biotest has a debt balance of 912 M EUR this year.
Biotest Liabilities 2024
Biotest Liabilities
912 M EUR
Biotest Dividend yield
0.12 %
Ticker
BIO.DE
ISIN
DE0005227201
WKN
522720
In 2024, Biotest's total liabilities amounted to 912 M EUR, a 9.63% difference from the 831.9 M EUR total liabilities in the previous year.
Biotest Aktienanalyse
What does Biotest do?
Biotest AG is an innovative and successful company that operates in the fields of medicine, pharmacy, and biotechnology. It was founded in 1946 by Dr. Carl Adolf Vorherr in Dreieich near Frankfurt am Main. The company's original focus was on the development, production, and distribution of blood plasma products. In the 1950s, Biotest expanded into the field of transfusion medicine and began to clinically examine and process blood from donors. It became a leading manufacturer of concentrate preparations for the treatment of immune deficiencies and blood coagulation disorders in the 1960s. In the 1970s, the company became a leading manufacturer of monoclonal and polyclonal antibodies and an important research and development facility for biotechnological applications. Biotest today is divided into five research and business areas: Hematology & Immunology, Clinical Immunology, Biotherapeutics, Dermatology, and Research and Development. The company is globally present with locations in Europe, North America, Asia, and South America. It employs over 2,500 people and its products are available in more than 90 countries. It invests in research and development to stay at the forefront of technology and improve global health. Biotest ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing Biotest's Liabilities
Biotest's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Biotest's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing Biotest's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
Biotest's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in Biotest’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about Biotest Stock
What were the liabilities of Biotest compared to the previous year?
The liabilities of Biotest have increased by 9.63% increased compared to the previous year.
What are the consequences of high debt for investors of Biotest?
High liabilities can pose a risk for investors of Biotest, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in Biotest?
Low liabilities mean that Biotest has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of Biotest affect the company?
An increase in liabilities of Biotest can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of Biotest affect the company?
A decrease in the liabilities of Biotest can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of Biotest?
Some factors that can influence the liabilities of Biotest include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of Biotest so important for investors?
The liabilities of Biotest are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can Biotest take to modify the liabilities?
To change its liabilities, Biotest can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does Biotest pay?
Over the past 12 months, Biotest paid a dividend of 0.05 EUR . This corresponds to a dividend yield of about 0.12 %. For the coming 12 months, Biotest is expected to pay a dividend of 0 EUR.
What is the dividend yield of Biotest?
The current dividend yield of Biotest is 0.12 %.
When does Biotest pay dividends?
Biotest pays a quarterly dividend. This is distributed in the months of June, June, June, September.
How secure is the dividend of Biotest?
Biotest paid dividends every year for the past 2 years.
What is the dividend of Biotest?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Biotest located?
Biotest is assigned to the 'Health' sector.
Wann musste ich die Aktien von Biotest kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Biotest from 9/4/2017 amounting to 0.05 EUR, you needed to have the stock in your portfolio before the ex-date on 8/31/2017.
When did Biotest pay the last dividend?
The last dividend was paid out on 9/4/2017.
What was the dividend of Biotest in the year 2023?
In the year 2023, Biotest distributed 0 EUR as dividends.
In which currency does Biotest pay out the dividend?
The dividends of Biotest are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Biotest
Our stock analysis for Biotest Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biotest Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
